相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Antihyperglycemic Therapies With Expansions of US Food and Drug Administration Indications to Reduce Cardiovascular Events: Prescribing Patterns Within an Academic Medical Center
Arsalan Hamid et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2020)
Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program
Jing Luo et al.
JAMA NETWORK OPEN (2020)
Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease Insights From Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD)
Suzanne V. Arnold et al.
CIRCULATION (2019)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Antidiabetic treatment patterns and specialty care utilization among patients with type 2 diabetes and cardiovascular disease
Kevin M. Pantalone et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017
Thomas R. Einarson et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Economic Burden of Cardiovascular Disease in Type 2 Diabetes: A Systematic Review
Thomas R. Einarson et al.
VALUE IN HEALTH (2018)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F. Hernandez et al.
LANCET (2018)
Diabetes Complications Severity Index (DCSI)-Update and ICD-10 translation
William P. Glasheen et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2017)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Gaps and barriers in the control of blood glucose in people with type 2 diabetes
Lawrence Blonde et al.
DIABETES & VASCULAR DISEASE RESEARCH (2017)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Sulfonylureas and their use in clinical practice
Daniele Sola et al.
ARCHIVES OF MEDICAL SCIENCE (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 Countries
Hude Quan et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2011)
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
N. Sarwar et al.
LANCET (2010)
The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients
Mary E. Charlson et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2008)
分享论文
